Interpreting the RAPIDO trial: factors to consider - Authors' reply.

Saved in:
Bibliographic Details
Title: Interpreting the RAPIDO trial: factors to consider - Authors' reply.
Authors: Bahadoer RR; Department of Surgery, Leiden University Medical Center, Leiden, Netherlands., Dijkstra EA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands., van Etten B; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands., Marijnen CAM; Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Putter H; Department of Biomedical Datasciences, Leiden University Medical Center, Leiden, Netherlands., Kranenbarg EM; Department of Surgery, Leiden University Medical Center, Leiden, Netherlands., Nilsson PJ; Department of Surgery, Karolinska University Hospital, Stockholm, Sweden., Glimelius B; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., van de Velde CJH; Department of Surgery, Leiden University Medical Center, Leiden, Netherlands., Hospers GAP; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9700 RB, Netherlands. Electronic address: g.a.p.hospers@umcg.nl.
Source: The Lancet. Oncology [Lancet Oncol] 2021 Mar; Vol. 22 (3), pp. e90-e91.
Publication Type: Letter; Comment
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(21)00087-5